Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and related comorbidities.
The partnership aims to enable oral administration of biologic drugs traditionally injected due to poor gastrointestinal absorption. Credit: BlurryMe / Shutterstock.com.
Subscribe to our email newsletter
Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered royalties on future product sales.
The partnership aims to enable oral administration of biologic drug candidates that are traditionally injected due to poor absorption in the gastrointestinal tract.
Vivtex will license to Novo Nordisk select oral drug-delivery technologies and is set to receive research funding, upfront payments, and milestone payments up to $2.1bn, along with tiered royalties on future product sales.
The partnership aims to enable oral administration of biologic drug candidates that are traditionally injected due to poor absorption in the gastrointestinal tract.
Vivtex CEO and co-founder Thomas von Erlach said: “Making biologics oral has been one of the most difficult challenges in drug delivery. Vivtex was founded to systematically solve this problem by integrating high-throughput experimentation with computational and AI-enabled analytics.
“Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection.”
Vivtex’s platform integrates drug-delivery technologies, gastrointestinal screening assays, AI tools, and computational simulation to optimise oral delivery of biologic medicines.
The system is designed for high oral bioavailability and consistent performance in humans.
After research and formulation selection phases, Novo Nordisk will oversee global development, regulatory activities, manufacturing, and commercialisation of any successful products.
Last month, the company initiated a new phase in its ongoing partnership with Aspect Biosystems, which focuses on curative cellular medicines to treat diabetes.
